Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)

Càncer d'ovaris; Biomarcadors tumorals

Bibliographic Details
Authors: Swisher, Elizabeth M., Kwan, Tanya T., Oza, Amit M., Tinker, Anna V., Ray-Coquard, Isabelle, Oaknin Benzaquen, Ana Mazaltob
Format: article
Status:Published version
Publication Date:2021
Country:España
Institution:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repository:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:11351/6853
Online Access:https://hdl.handle.net/11351/6853
http://hdl.handle.net/11351/6853
Access Level:Open access
Keyword:Ovaris - Càncer - Tractament
Ovaris - Càncer - Recaiguda
DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Ovarian Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Recurrence, Local
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias ováricas
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
ENFERMEDADES::neoplasias::procesos neoplásicos::recurrencia neoplásica local
id ES_cbf65dca777b8dfa0e1ffdfb5a704c5f
oai_identifier_str oai:recercat.cat:11351/6853
network_acronym_str ES
network_name_str España
repository_id_str
spelling Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)Swisher, Elizabeth M.Kwan, Tanya T.Oza, Amit M.Tinker, Anna V.Ray-Coquard, IsabelleOaknin Benzaquen, Ana MazaltobOvaris - Càncer - TractamentOvaris - Càncer - RecaigudaDISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Ovarian NeoplasmsOther subheadings::Other subheadings::Other subheadings::/drug therapyDISEASES::Neoplasms::Neoplastic Processes::Neoplasm Recurrence, LocalENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias ováricasOtros calificadores::Otros calificadores::Otros calificadores::/farmacoterapiaENFERMEDADES::neoplasias::procesos neoplásicos::recurrencia neoplásica localCàncer d'ovaris; Biomarcadors tumoralsCáncer de ovarios; Biomarcadores tumoralesOvarian cancer; Tumour biomarkersARIEL2 (NCT01891344) is a single-arm, open-label phase 2 study of the PARP inhibitor (PARPi) rucaparib in relapsed high-grade ovarian carcinoma. In this post hoc exploratory biomarker analysis of pre- and post-platinum ARIEL2 samples, RAD51C and RAD51D mutations and high-level BRCA1 promoter methylation predict response to rucaparib, similar to BRCA1/BRCA2 mutations. BRCA1 methylation loss may be a major cross-resistance mechanism to platinum and PARPi. Genomic scars associated with homologous recombination deficiency are irreversible, persisting even as platinum resistance develops, and therefore are predictive of rucaparib response only in platinum-sensitive disease. The RAS, AKT, and cell cycle pathways may be additional modulators of PARPi sensitivity.Nature ResearchInstitut Català de la Salut[Swisher EM] University of Washington, Seattle, WA, USA. [Kwan TT] Clovis Oncology, Inc., Boulder, CO, USA. [Oza AM] Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. [Tinker AV] BC Cancer—Vancouver, Vancouver, BC, Canada. [Ray-Coquard I] GINECO, Centre Léon Bérard and University Claude Bernard, Lyon, France. [Oaknin A] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, SpainVall d'Hebron Barcelona Hospital Campus202220222021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfapplication/pdfhttps://hdl.handle.net/11351/6853http://hdl.handle.net/11351/6853Scientiareponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésNature Communications;12https://doi.org/10.1038/s41467-021-22582-6Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:11351/68532026-05-29T05:05:01Z
dc.title.none.fl_str_mv Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
title Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
spellingShingle Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
Swisher, Elizabeth M.
Ovaris - Càncer - Tractament
Ovaris - Càncer - Recaiguda
DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Ovarian Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Recurrence, Local
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias ováricas
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
ENFERMEDADES::neoplasias::procesos neoplásicos::recurrencia neoplásica local
title_short Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
title_full Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
title_fullStr Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
title_full_unstemmed Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
title_sort Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
dc.creator.none.fl_str_mv Swisher, Elizabeth M.
Kwan, Tanya T.
Oza, Amit M.
Tinker, Anna V.
Ray-Coquard, Isabelle
Oaknin Benzaquen, Ana Mazaltob
author Swisher, Elizabeth M.
author_facet Swisher, Elizabeth M.
Kwan, Tanya T.
Oza, Amit M.
Tinker, Anna V.
Ray-Coquard, Isabelle
Oaknin Benzaquen, Ana Mazaltob
author_role author
author2 Kwan, Tanya T.
Oza, Amit M.
Tinker, Anna V.
Ray-Coquard, Isabelle
Oaknin Benzaquen, Ana Mazaltob
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Institut Català de la Salut
[Swisher EM] University of Washington, Seattle, WA, USA. [Kwan TT] Clovis Oncology, Inc., Boulder, CO, USA. [Oza AM] Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. [Tinker AV] BC Cancer—Vancouver, Vancouver, BC, Canada. [Ray-Coquard I] GINECO, Centre Léon Bérard and University Claude Bernard, Lyon, France. [Oaknin A] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
dc.subject.none.fl_str_mv Ovaris - Càncer - Tractament
Ovaris - Càncer - Recaiguda
DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Ovarian Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Recurrence, Local
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias ováricas
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
ENFERMEDADES::neoplasias::procesos neoplásicos::recurrencia neoplásica local
topic Ovaris - Càncer - Tractament
Ovaris - Càncer - Recaiguda
DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Ovarian Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Recurrence, Local
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias ováricas
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
ENFERMEDADES::neoplasias::procesos neoplásicos::recurrencia neoplásica local
description Càncer d'ovaris; Biomarcadors tumorals
publishDate 2021
dc.date.none.fl_str_mv 2021
2022
2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11351/6853
http://hdl.handle.net/11351/6853
url https://hdl.handle.net/11351/6853
http://hdl.handle.net/11351/6853
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Nature Communications;12
https://doi.org/10.1038/s41467-021-22582-6
dc.rights.none.fl_str_mv Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Nature Research
publisher.none.fl_str_mv Nature Research
dc.source.none.fl_str_mv Scientia
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419634099224576
score 15,811543

Similar Items